HHS unexpectedly canceled a meeting of the U.S. Preventive Services Task Force, prompting fears it may be dismantled following similar moves by Secretary Robert F. Kennedy Jr. at other federal health agencies.
On November 16, 2023, the U.S. Food and Drug Administration (FDA) approved capivasertib (Truqap) with fulvestrant for adult patients with hormone receptor–positive, HER2-negative locally advanced or m...
2023 brought record-breaking heat waves in the United States, significantly impacting vulnerable groups. Analysis by the CDC revealed a substantial number of heat-related illness (HRI) emergency department visits, resulting in multiple public health alerts.
Results from a trial reveal that Eli Lilly's tirzepatide, a weight loss drug, reduces the risk of heart failure outcomes by 38% compared to a placebo for obese adults, with significant weight loss and improved symptoms. Novo Nordisk's Wegovy also shows promise in reducing heart failure symptoms.
Reuters
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Rezolute Inc has received FDA approval to proceed with its late-stage trial for a new treatment addressing low blood sugar in individuals with congenital hyperinsulinism, with potential U.S. enrollment expected to start in early 2025.
Novo Nordisk's latest trial reveals positive effects of weight-loss drug on liver health, pointing to potential benefits beyond weight management. #LiverHealth #Semaglutide
March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.